Search

Jennifer L Lachey

from Lincoln, MA
Age ~51
Get Report
Also known as:
Jennifer J Lachey, Jennfer Lachey, Jennefer Lachy
Phone and address:
99 Tower Rd, Lincoln Center, MA 01773
Related to:
Anthony Garcia, 54
Connected to:
Ayoub Lachgar, 38Hassan Lachhab, 53Ambika Lachhu, 39Adolfo Lachica, 58Alberto A Lachica, 76Angela A Lachica, 43Edna G Lachica, 68Gary K Lachica, 63Gregory C Lachica, 61John N Lachica, 72

Jennifer Lachey Phones & Addresses

  • 99 Tower Rd, Lincoln, MA 01773
  • 19 Pondview Rd #2, Arlington, MA 02474
  • 13 Davis St, Belmont, MA 02478
  • 18 Florence St, Cambridge, MA 02139
  • 20 Lopez St, Cambridge, MA 02139
  • 2238 Ravine St, Cincinnati, OH 45219
  • Waltham, MA

Publications

Us Patents

Methods For Increasing Adiponectin

View page
US Patent:
20100183624, Jul 22, 2010
Filed:
Jan 13, 2010
Appl. No.:
12/657146
Inventors:
Jasbir Seehra - Lexington MA, US
Ravindra Kumar - Acton MA, US
Jennifer Lachey - Arlington MA, US
Alan Koncarevic - Boston MA, US
International Classification:
A61K 38/02
A61K 39/395
A61K 31/7088
A61P 5/00
A61P 3/10
US Classification:
4241581, 514 2, 4241781, 514 44 R
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.

Methods For Treating Fatty Liver Disease

View page
US Patent:
20110129469, Jun 2, 2011
Filed:
Nov 3, 2010
Appl. No.:
12/939084
Inventors:
Alan Koncarevic - Boston MA, US
Jennifer Lachey - Arlington MA, US
Jasbir Seehra - Lexington MA, US
Matthew L. Sherman - Newton MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
A61K 39/395
A61K 38/16
A61P 1/16
A61K 31/7088
A61K 38/18
US Classification:
4241341, 514 213, 514 212, 4241721, 514 44 A, 514 76
Abstract:
In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.

Actriib Proteins And Variants And Uses Therefore Relating To Utrophin Induction For Muscular Dystrophy Therapy

View page
US Patent:
20110135638, Jun 9, 2011
Filed:
Nov 17, 2010
Appl. No.:
12/948411
Inventors:
Jasbir Seehra - Lexington MA, US
Jennifer Lachey - Arlington MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
A61K 39/395
A61K 38/17
A61K 31/7088
A61P 21/00
US Classification:
4241331, 514 213, 514 212, 4241581, 514 44 A
Abstract:
In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand.

Methods For Increasing Adiponectin

View page
US Patent:
20120156204, Jun 21, 2012
Filed:
Feb 24, 2012
Appl. No.:
13/404593
Inventors:
Jasbir Seehra - Lexington MA, US
Ravindra Kumar - Acton MA, US
Jennifer Lachey - Arlington MA, US
Alan Koncarevic - Chicago IL, US
Assignee:
Acceleron Pharma, Inc. - Cambridge MA
International Classification:
A61K 39/395
A61P 3/04
A61P 3/10
A61P 3/06
A61P 9/10
A61P 3/08
US Classification:
4241351, 4241581, 4241331, 4241361, 4241431
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.

Methods Of Using Alk2 Inhibitors

View page
US Patent:
20220401445, Dec 22, 2022
Filed:
Apr 30, 2021
Appl. No.:
17/246577
Inventors:
- Lexington MA, US
Jennifer LACHEY - Lincoln MA, US
Elissa FURUTANI - Belmont MA, US
International Classification:
A61K 31/5025
A61K 31/496
A61K 31/517
A61P 7/06
A61K 9/00
Abstract:
The invention relates to methods of treating multiple osteochondroma and anemia resulting from iron imbalance using small molecule ALK2 inhibitors.

Methods Of Using Activin Receptor Type Iib Variants

View page
US Patent:
20230087128, Mar 23, 2023
Filed:
Sep 15, 2022
Appl. No.:
17/945328
Inventors:
- Lexington MA, US
Jennifer LACHEY - Lincoln MA, US
Elissa FURUTANI - Belmont MA, US
International Classification:
A61K 38/17
A61K 35/19
C07K 14/78
Abstract:
The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.

Activin Receptor Type Ii Chimeras And Methods Of Use Thereof

View page
US Patent:
20230079602, Mar 16, 2023
Filed:
Sep 15, 2022
Appl. No.:
17/945299
Inventors:
- Lexington MA, US
Jennifer LACHEY - Lincoln MA, US
Claire TSENG - Newton MA, US
Jason O'NEILL - Lake Forest Park WA, US
Henning THØGERSEN - Farum, DK
Elissa FURUTANI - Belmont MA, US
International Classification:
C07K 14/71
A61P 21/00
A61P 19/08
A61P 7/06
A61P 11/00
A61P 3/04
A61P 7/04
A61P 7/00
Abstract:
The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and/or pulmonary hypertension.

Activin Receptor Type Iia Variants And Methods Of Use Thereof

View page
US Patent:
20210275637, Sep 9, 2021
Filed:
May 24, 2021
Appl. No.:
17/327914
Inventors:
- Lexington MA, US
Jennifer LACHEY - Lincoln MA, US
Assignee:
Keros Therapeutics, Inc. - Lexington MA
International Classification:
A61K 38/18
A61K 47/65
A61P 19/08
C07K 14/71
C07K 14/76
C12N 15/85
C12P 21/02
Abstract:
The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.
Control profile
Jennifer L Lachey from Lincoln, MA, age ~51 Get Report